Graft-Versus-Host Disease

The FDA granted priority review to the allogeneic cell therapy remestemcel-L for the treatment of children with steroid-refractory acute graft-versus-host disease, according to the agent’s manufacturer.

A myeloablative fractionated busulfan regimen with post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis appeared feasible for older patients with hematologic malignancies, according to results of a single-arm phase 2 study presented at TCT | Transplantation & Cellular Therapy Meetings.

ORLANDO — Individualized dosing of rabbit anti-thymocyte globulin significantly improved CD4-positive T-cell recovery after allogeneic hematopoietic stem cell transplantation among children, according to results of the open-label phase 2 PARACHUTE study presented at TCT | Transplantation & Cellular Therapy Meetings.

Patterns of microbiota disruption, marked by loss of intestinal diversity and single taxa domination, appeared similar among a cohort of patients undergoing allogeneic hematopoietic stem cell transplantation across various centers and geographic areas, according to findings published in The New England Journal of Medicine.

ORLANDO — The novel antiviral agent letermovir appeared effective for primary cytomegalovirus prevention among haploidentical stem cell transplant recipients, according to results of a single-center chart review presented at TCT | Transplantation & Cellular Therapy Meetings.

The final patient has been enrolled in a phase 1/2 study of Elate Ocular topical fibrinogen-depleted human platelet lysate biologic for the treatment of dry eye secondary to graft-versus-host disease, Cambium Medical Technologies announced in a press release.

The number of APPs continues to increase considerably in the U.S., with higher health care costs and physician shortages — particularly in rural areas lacking health care access — driving this increase.

Usama Gergis, MD, MBA, has been named director of the bone marrow transplant and immune cellular therapy program at Sidney Kimmel Cancer Center at Jefferson.

Natural killer cells transduced with chimeric antigen receptors induced high response rates among patients with relapsed or refractory CD19-positive non-Hodgkin lymphoma and chronic lymphocytic leukemia, according to results of a phase 1/phase 2 study published in The New England Journal of Medicine.

In 1984, a teenage boy was lying in his hospital bed, his body ravaged by acute graft-versus host disease.